ARVN - Arvinas, Inc. So'nggi Yangiliklar | Finranks

ARVN - Arvinas, Inc. So'nggi Yangiliklar | Finranks

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease –

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.63 per share a year ago.

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and Director – – Company to host conference call today at 8:00 a.m.

Arvinas to Participate in Upcoming Investor Conferences

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here , at 1:10 p.m.

Videolar

No Data

There is no data to display